In summary, we now have two large prospective, double blind, placebo-controlled studies demonstrating that two different GLP-1 receptor agonists can reduce cardiovascular events in T2DM patients at high risk for CV disease
But If I have a high-risk patient with heart disease, with sleep apnea and advanced liver disease, this could be a lifesaving medication. Stateline is part of States Newsroom , a national nonprofit news organization focused on state policy
So, when a compound like BPC-157 gains this much traction, we feel it's our responsibility to provide an unflinching, science-backed perspective
You wont be surprised at checkout by hidden fees
What People Are Reporting Across TikTok, Reddit, and Facebook support groups, patients are swapping stories of sudden dental issues that seem to appear after beginning GLP-1 treatment
Misclassification in administrative claims data: quantifying the impact on treatment effect estimates